OptimizeRx (OPRX) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
1 Jul, 2026Corporate profile and market position
Leading technology provider connecting life sciences, physicians, and patients to improve therapy initiation and adherence.
Operates the largest U.S. patient point-of-care network, reaching most physicians and patients.
Employs about 130 staff across the U.S. and Croatia, with revenue per FTE exceeding $800K.
Listed on NASDAQ with a market cap of ~$101M and $20.2M in cash as of Q1 2026.
Strategic challenges and solutions
Addresses pharma challenges: brand visibility, specialty medication shift, EHR overload, affordability, interoperability, and script abandonment.
Mission combines human ingenuity, AI, and technology to transform life-science marketing and patient connections.
Platform connects over 2 million HCPs and 240 million patients, supporting ~400 brands.
Technology and platform capabilities
Dynamic Audience Activation Platform (DAAP) delivers predictive, privacy-safe marketing across clinical and personal platforms.
DAAP deals typically range from $0.5M to $1.5M, supporting omnichannel marketing execution.
First to enable programmatic buying of authenticated EHR inventory at scale, unlocking access to 90% of U.S. digital display spend.
Latest events from OptimizeRx
- Q2 2024 revenue up 36% to $18.8M, gross margin 62.2%, and strong DAAP momentum.OPRX
Q2 20248 Jul 2026 - Directors elected, executive pay and equity plan increase approved, evergreen provision rejected.OPRX
AGM 202613 Jun 2026 - AI-powered point-of-care platform drives pharma ROI and growth through EHR integration and DSPs.OPRX
46th Annual William Blair Growth Stock Conference4 Jun 2026 - Proposal seeks a five-year evergreen equity plan amendment with strong governance and oversight.OPRX
Proxy filing1 Jun 2026 - Q1 2026 revenue fell 10%, but profitability improved and guidance remains strong.OPRX
Q1 202613 May 2026 - Record 2025 growth, margin expansion, and $10M buyback set a strong but cautious 2026 outlook.OPRX
Q4 20256 May 2026 - Board recommends approval of all proxy proposals, including equity plan changes and auditor ratification.OPRX
Proxy filing30 Apr 2026 - Scalable platform drives pharma brand engagement and revenue growth in a large digital market.OPRX
Corporate presentation24 Mar 2026 - Q3 2025 saw 22% revenue growth, margin expansion, and raised guidance for 2025–2026.OPRX
Q3 20253 Feb 2026